Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021
Cash flows from operating activities
Net loss	$ (42,750)	$ (53,204)
Adjustments to reconcile net loss to net cash used in operating activities
Depreciation	45	5
Amortization of right-of-use assets - operating	148
Stock-based compensation	7,575	368
Accretion of marketable securities, net	(109)
Non-cash interest - related party		99
Change in fair value of notes and derivative - related party		11,051
Change in fair value of Series A tranche liability		5,476
Acquired in-process research and development		21,781
Changes in operating assets and liabilities
Prepaid expenses and other assets	2,677	(1,737)
Operating lease liabilities	(136)
Accounts payable (includes related party amounts of $77 and ($421), respectively)	1,171	171
Accrued expenses (includes related party amounts of ($101) and $265, respectively)	3,861	3,068
Net cash used in operating activities	(27,518)	(12,922)
Cash flows from investing activities
Acquisition of Oppilan and Zomagen, net of cash		1,899
Purchases in marketable securities, available-for-sale	(125,397)
Proceeds from maturities of marketable securities, available-for-sale	127,210
Purchases of property and equipment	(66)	(11)
Net cash provided by investing activities	1,747	1,888
Cash flows from financing activities
Proceeds from issuance of Series A convertible preferred stock, net of offering costs		113,415
Deferred offering costs		(300)
Proceeds from exercise of stock options	220	25
Proceeds from issuance of common stock under employee stock purchase plan	115
Proceeds from issuance of SAFE notes, net		450
Net cash provided by financing activities	335	113,590
Effect of exchange rates on cash and cash equivalents	(12)	(12)
Net increase (decrease) in cash and cash equivalents	(25,448)	102,544
Cash and cash equivalents, beginning of period	70,791	244
Cash and cash equivalents, end of period	45,343	102,788
Supplemental disclosure for non-cash activities
Conversion of promissory and SAFE notes - related party		38,911
Stock issued for the acquisition of Oppilan and Zomagen		21,345
Unpaid deferred offering costs		$ 453
Unrealized loss on marketable securities, available-for-sale	$ (1,221)